

PATENT

Customer No. 22,852

Attorney Docket No. 08702.0005-00000

- ii) determining the effect of the test compound on the activity of said SLIC-1 protein.

27. (New) A method for identifying a compound which increases the activity of a SLIC-1 protein comprising:

- i) contacting said SLIC-1 protein with a test compound; and
ii) determining the effect of the test compound on activity of said SLIC-1 protein.

28. (New) The method of claim 26 or 27, wherein said SLIC-1 protein comprises at least 150 contiguous amino acid of SEQ ID NO:1.

29. (New) The method of claim 28, wherein said SLIC-1 protein comprises at least 200 contiguous amino acid of SEQ ID NO:1.

30. (New) The method of claim 29, wherein said SLIC-1 protein comprises the amino acid of SEQ ID NO:1.

31. (New) The method as in claim 26 or 27, wherein said SLIC-1 protein comprises at least 150 contiguous amino acids of a sequence which is at least 90% identical to SEQ ID NO:2.

32. (New) The method of claim 31, wherein said SLIC-1 protein comprises at least 200 contiguous amino acids of a sequence which is at least 90% identical to SEQ ID NO:2.

33. (New) The method of claim 32, wherein said SLIC-1 protein comprises a sequence which is at least 90% identical to SEQ ID NO:2.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

PATENT
Customer No. 22,852
Attorney Docket No. 08702.0005-00000

34. (New) The method as in claim 26 or 27, wherein said SLIC-1 protein comprises at least 150 contiguous amino acids of a sequence encoded by a nucleic acid of SEQ ID NO:1.

35. (New) The method as in claim 34, wherein said SLIC-1 protein comprises at least 200 contiguous amino acids of a sequence encoded by a nucleic acid of SEQ ID NO:1.

36. (New) The method as in claim 35, wherein said SLIC-1 protein comprises an amino acids sequence encoded by a nucleic acid of SEQ ID NO:1.

37. (New) The method as in claim 26 or 27, wherein said SLIC-1 protein comprises at least 150 contiguous amino acids encoded by a nucleic acid which is at least 90% identical to SEQ ID NO:1.

38. (New) The method as in claim 37, wherein said SLIC-1 protein comprises at least 200 contiguous amino acids encoded by a nucleic acid which is at least 90% identical to SEQ ID NO:1.

39. (New) The method as in claim 37, wherein said SLIC-1 protein comprises an amino acid sequence encoded by a nucleic acid which is at least 90% identical to SEQ ID NO:1.

40. (New) The method as in claim 26 or 27, wherein said polypeptide comprises at least 25 contiguous amino acids of SEQ ID NO:2, wherein said polypeptide is capable of interacting with at least one of the following: (1) a protein comprising a SH2 domain; (2) intracellular domain of PSGL-1; (3) intracellular signaling molecule; and (4) a cytoskeletal protein.

41. (New) The method as in claim 40, wherein said polypeptide comprises at least 30 contiguous amino acids of SEQ ID NO:2.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.406.4000
Fax 202.408.4400
www.finnegan.com

PATENT

Customer No. 22,852

Attorney Docket No. 08702.0005-00000

42. (New) The method as in claim 41, wherein said polypeptide comprises at least 50 contiguous amino acids of SEQ ID NO:2

43. (New) The method as in claim 42, wherein said polypeptide comprises at least 100 contiguous amino acids of SEQ ID NO:2;

44. (New) The method as in claim 26 or 27, wherein said polypeptide comprises residues 160 to 226 of SEQ ID NO:2.

45. (New) The method as in claim 26 or 27, wherein said polypeptide comprises residues 1 to 226 of SEQ ID NO:2.

46. (New) The method as in claim 26 or 27, wherein said polypeptide comprises at least one immunoreceptor tyrosine based motif.

47. (New) The method as in claim 26 or 27, wherein said polypeptide is fused to GST.

48. (New) The method as in claim 26 or 27, wherein said polypeptide is fused to a T7 protein tag. --

REMARKS

Claims 26-48 are pending upon entry of this Amendment. Amendments made in claim 26 are shown in the attached Appendix. Support for the amendments in claim 26 and new claims 27-58 is found throughout the specification and original claims as filed. Specifically, support for amended claim 26 and new claim 27 can be found on p. 7, lines 34-39; p. 8, lines 1-11; p.10, lines 28-38; and p. 11, lines 1-4, of the specification. Support for claims 28-30 can be found on p. 14, line 15, of the specification. Support for claims 31-35 and 37-39 can be found on p. 13, line 36-39; p. 14, line 15; p. 24, lines 20-25; and p. 24, lines 32-39, of the specification. Support for

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.406.4000
Fax 202.406.4400
www.finnegan.com